Group 1: Core Development Strategy - The core strategy revolves around four major platforms: scale manufacturing, industry chain integration, omnichannel sales, and large variety R&D [2][3] - The scale manufacturing platform aims to increase the company's herbal material processing capacity from 25,000 tons to 60,000 tons annually, supporting future sales growth [2][3] - The industry chain integration platform seeks to enhance product lines through licensing and branding strategies [2][3] Group 2: R&D Focus Areas - The company is focusing on the "Tian Ning Tong Luo" project for diabetes and its complications, which has over 10 years of clinical experience and is currently in Phase 3 clinical trials [3][4] - The "Huang Lian Jie Du Wan" project, a new type of traditional Chinese medicine, has completed Phase 2 and 3 clinical trials with 840 cases enrolled, targeting various diseases [4] Group 3: Sales and Marketing Optimization - High sales expense rates are attributed to a previous "big package" model, unclear product planning, and weak channel management [5] - The company is reforming its marketing system, transitioning from a big package model to a direct sales model, with 15 provinces already completed [5] - A market supervision department has been established to enhance oversight of business activities and financial management [5] Group 4: Financial Goals and Recovery Path - The revenue target for 2025 is projected at 4 billion CNY, with a net profit of 120 million CNY [6] - Recovery strategies include product price optimization, improving sales efficiency through direct sales reforms, and integrating advantageous products to enhance profitability [6] Group 5: Investment in Subsidiaries - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. is a subsidiary in which the company holds a 17.6926% stake, focusing on innovative drug research and development [6]